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Tradeoff between metabolic i-proteasome addiction and
immune evasion in triple-negative breast cancer
Alaknanda Adwal1 , Priyakshi Kalita-de Croft2 , Reshma Shakya3, Malcolm Lim2, Emarene Kalaw2, Lucinda D Taege2,4,
Amy E McCart Reed2 , Sunil R Lakhani2,4 , David F Callen5,*, Jodi M Saunus2,*
In vitro studies have suggested proteasome inhibitors could be
effective in triple-negative breast cancer (TNBC). We found that
bortezomib and carfilzomib induce proteotoxic stress and apo-
ptosis via the unfolded protein response (UPR) in TNBC cell lines,
with sensitivity correlated with expression of immuno-(PSMB8/9/
10) but not constitutive-(PSMB5/6/7) proteasome subunits.
Equally, the transcriptomes of i-proteasome–high human TNBCs
are enriched with UPR gene sets, and the genomic copy number
landscape reflects positive selection pressure favoring i-proteasome
activity, but in the setting of adjuvant treatment, this is actually
associated with favorable prognosis. Tumor expression of PSMB8
protein (β5i) is associated with levels of MHC-I, interferon-γ–
inducible proteasome activator PA28β, and the densities of stromal
antigen-presenting cells and lymphocytes (TILs). Crucially, TILs were
protective among TNBCs that maintain high β5i but did not stratify
survival amongst β5i-low TNBCs. Moreover, β5i expression was
lower in brain metastases than in patient-matched primary breast
tumors (n = 34; P = 0.007), suggesting that suppression contributes
to immune evasion and metastatic progression. Hence, inhibiting
proteasome activity could be counterproductive in the adjuvant
treatment setting because it potentiates anti-TNBC immunity.
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Introduction
The ubiquitin-proteasome system (UPS) is vital for cellular ho-
meostasis, acting to regulate protein expression and eradicate
oxidized, misfolded proteins. The proteasome is its 2.5-MD catalytic
engine—the major cellular protein recycling complex that degrades
poly-ubiquitinated substrates (Sorokin et al, 2009). Its 20S core
comprises 28 subunits arranged in four heptameric rings—two
outer “alpha” and two inner “beta” rings surround a central pore
through which unfolded proteins pass as they are cleaved. Three
subunits (six per core) provide a complete spectrum of proteolytic
activity after acidic, basic, and hydrophobic amino acids: β1 cas-
pase-, β2 trypsin-, and β5 chymotrypsin-like (encoded by PSMB6,
PSMB7, and PSMB5). Proteasome substrate specificity, throughput,
and subcellular localization are regulated by activator complexes
that dock with the core, forming single- and double-capped ho-
loenzymes. A 19S cap is essential for de-ubiquitination, translo-
cation, and ATP-dependent substrate unfolding. Under normal
conditions, 19S-capped 20S core complexes the predominant
proteasome species present in the cell (“constitutive” protea-
somes). However, in certain conditions, the core can also dock with
PA28α/β, PA28γ, and PA200 caps, which lack catalytic activity but
widen the 20S pore and increase throughput (reviewed in Kors et al
[2019]).
In addition to posttranslational regulation and buffering against
proteotoxic stress, the UPS is also the major source of peptides
presented to the immune system via MHC class-I molecules. Ac-
cordingly, IFN-γ is a potent stimulus for proteasome compositional
change. IFN-γ down-regulates constitutive proteasome subunit
genes and induces the genes that encode PA28α and PA28β (PSME1
and PSME2) and alternative 20S core subunits β1i, β2i, and β5i
(PSMB9,PSMB10, andPSMB8), which increases proteasome throughput
and produces a varied repertoire of MHC-I epitopes via different
cleavage site preferences (Aki et al, 1994). Hence, in the context of an
immunologic challenge, IFN-γ–stimulated cells express a variety of
hybrid “immuno(i)-proteasome” complexes.
Proteasome inhibitors (PIs) such as bortezomib and carfilzomib
are effective for treatment of multiple myeloma and mantle cell
lymphoma. Their clinical activity is partly attributed to disruption of
the UPS, which stabilizes apoptotic proteins (e.g., p53 and Bcl2) and
IκBα, inhibitor of the NFκB pro-survival pathway. Both inhibitors
bind to β5 and β5i subunits, but carfilzomib binds irreversibly and
has a favorable side effect profile (Cromm & Crews, 2017). PIs also
exploit metabolic addiction to the proteasome. By promoting ac-
cumulation of misfolded and oxidized protein aggregates in the ER,
they trigger the unfolded protein response (UPR), a sensing mechanism
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that promotes apoptosis in the event of unsustainably high rates of
cellular metabolism (Sorokin et al, 2009). In cancer, rapid division of
cells with mutated genomes should incite the UPR, but strategies
evolve to cope with proteotoxicity, including proteasome over-
expression (Adams, 2004). The UPR-inducing activity of PIs is at-
tributed mainly to inhibition of constitutive proteasomes, based on
a persisting assumption that this complex is the most abundant in
non-hematologic tissues (Roeten et al, 2018). However, solid tumors
also express the i-proteasome (Altun et al, 2005; Ho et al, 2007), and
this could represent an efficient means for maintaining a con-
centration of toxic protein aggregates below the UPR induction
threshold (Shringarpure et al, 2003).
Triple-negative breast cancers (TNBCs) comprise 15–20% of
invasive breast carcinomas. They lack clinically significant
expression of first-line systemic drug therapy targets (estro-
gen receptor, human epidermal growth factor receptor-2
[HER2]), are typically high-grade, are metabolically active,
and often exhibit basal-like and/or mesenchymal phenotypes
(Perou et al, 2000; Prat et al, 2010). Cytotoxic chemotherapy is a
mainstay of clinical management, but 40–80% of patients still
experience distant relapse and premature death, often in-
volving visceral and brain metastases (Fulford et al, 2007;
Pusztai et al, 2019). TNBC exhibits considerable molecular and
clinical heterogeneity, unsurprising given theirs is a diagnosis
of exclusion. Identifying biomarkers and therapeutic targets re-
main top research priorities. Promising recent developments have
centered on exploiting the predictive and therapeutic significance
of tumor-infiltrating lymphocytes (TILs). There is now international
consensus that the presence and density of TILs in pretreatment
diagnostic specimens predicts the response to neoadjuvant che-
motherapy and also to second-line treatment where a low-moderate
residual disease burden remains (Loi et al, 2019; Luen et al, 2019).
Thus, despite the systemic immunosuppression experienced by
patients undergoing active treatment, the presence of TILs before
this indicates the capacity of the host immune system to synergize
with chemotherapy.
In vitro and in vivo studies suggest that the proteasome is a
potential therapeutic target in TNBC (Cardoso et al, 2004; Petrocca
et al, 2013; Weyburne et al, 2017); however, preliminary clinical data
frommetastatic patients have beenmixed (Yang et al, 2006; Engel et
al, 2007; Schmid et al, 2008), and these trials pre-dated our un-
derstanding of the role of antitumor immunity in TNBC. This study
was undertaken to establish the molecular basis of PI activity and
relevance to the treatment of breast cancer, incorporating in vitro
mechanistic studies with genomic and protein-level data from large
human clinical sample cohorts.
Results and Discussion
Basal-like breast cancer cell lines are dependent on i-proteasome
activity
We initially characterized the relationship between proteasome subunit
expression and sensitivity to chemical or genetic inhibition of the
proteasome in vitro. Analysis of breast cancer cell line gene expression
data (Neve et al, 2006) indicated significantly higher expression of
i-relative to constitutive subunit in basal-A and claudin-low (basal-B)
lines than luminal and HER2+ cell lines (Fig 1A and B). We then
performed bortezomib and carfilzomib dose–response assays with a
panel of lines that model a range of proteasome subunit levels.
Expression of inducible relative to constitutive subunit RNA was anti-
correlated with response to both inhibitors (Figs 1C and S1A). The
relationship to PI sensitivity was most noticeable for PSMB8 (borte-
zomib LD50 correlation r − 0.76, P = 0.01), which was also evident at the
protein level (Fig 1D). There was no obvious relationship between
bortezomib sensitivity and baseline expression of the proteasome
activator cap subunit PA28γ (Fig 1D). This was not a consequence of
preferential i-proteasome inhibition, as the total proteasome activity
was suppressed in both MDA-MB-468 (i-prothigh, low bortezomib LD50);
and MCF-7 (i-protlow, low bortezomib LD50) (Fig 1E and F).
To rule out off-target effects, we transfected six lines with
PSMB8-targeted siRNAs and measured cell viability after 48 h using
flow cytometry. With the exception of MDA-MB-231, i-prothigh basal
lines were significantly more sensitive to PSMB8 depletion than
luminal lines (Fig 1Gi). MDA-MB-468 (basal/i-prothigh) and MCF7
(luminal/i-protlow) transfected with PSMB5-targeted siRNAs showed
no significant differences (Fig 1Gii, with confirmation of RNA and
protein knockdown in Fig S1B and C).
Bortezomib sensitivity correlates with the UPR in vitro
We reasoned that in cell lines addicted to the i-proteasome, phar-
macologic suppression of proteasome activity would cause ER stress
and trigger the UPR. Three parallel signaling axes mediate the UPR,
initiated by ER-membrane sensors: PRKR-like ER kinase (PERK), acti-
vating transcription factor 6α (ATF6α) and inositol-requiring protein 1α
(IRE1α). Induction of ATF4 marks PERK activation, whereas the IRE1α
branch leads to expression of a specific X-box transcription factor
splice isoform, XBP1s, which is associated with UPR-related effects in
the nucleus. Collectively, these pathways induce genes required for
protein folding, secretion, and clearance, or apoptosis if misfolding
cannot be resolved (Fig 2A [Wang & Kaufman, 2014]).
In line with our hypothesis, bortezomib treatment induced ATF4
in the four lines assayed (Fig 2B). Further analysis of i-proteasome–
dependent MDA-MB-468 cells revealed induction of XBP1s within 24 h
of treatment, concomitant with apoptosis markers and reduction of
pro-survival marker NFκB (Fig 2C). Thus, PSMB8-high, i-proteasome–
addicted BC cell lines exhibit UPR-driven apoptosis in response to
proteasome inhibition (Fig 2D). In terms of extrinsic modulation, IFN-
γ–induced PSMB8 in both MDA-MB-468 and MCF7 (Fig 2Ei), but there
was no effect on bortezomib sensitivity (Fig 2Eii). Assaying key IFN-γ
targets after treatment, including the IFN-stimulated response ele-
ment transactivator IRF1, confirmed the IFN-γ-IRF1-STAT1-PSMB8 axis
was intact (Fig 2F). Moreover, siRNA-mediated IRF1 depletion sup-
pressed target induction (Fig 2F). Thus, although i-proteasome levels
are associated with bortezomib sensitivity, this is not an exclusive
determinant. Sensitivity is likely to be linked to functional dependence
on the i-proteasome rather than the expression of its components.
i-proteasome induction is associated with the UPR in TNBC
To explore whether PI therapy is an appropriate strategy for
treatment of breast cancer, we mined several large genomic
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datasets: The Cancer Genome Atlas (TCGA; RNA-sequencing data
from 1,092 cases including 176 TNBCs) (Cancer Genome Atlas
Network, 2012), the Molecular Taxonomy of Breast Cancer Inter-
national Consortium (METABRIC; expression array data from 1,980
cases incl. 333 TNBCs) (Curtis et al, 2012), and KM-Plotter, a
composite of expression array studies with comprehensive
clinical annotation (Gyorffy et al, 2010). We interrogated these
datasets to identify patient subgroups that may benefit from PIs
and to test the hypothesis that i-proteasome activation is as-
sociated with the UPR in human tumors. Meta-analysis of ex-
pression data indicated that compared with estrogen receptor-positive
(ER+) and HER2+ tumors, TNBCs preferentially express i-proteasome
subunit genes over constitutive counterparts (β1i:β1, β2i:β2, and β5i:β5;
Fig 3A), and this is most evident in tumors with a claudin-low phenotype
(Fig 3B).
We then performed UPR gene set enrichment analysis (The
Gene Ontology Consortium, 2019) after ranking the transcriptome
according to correlations with PSMB8. The distributions of mul-
tiple UPR gene sets were skewed toward genes co-expressed with
PSMB8 (Fig 3C). This was evident in both datasets, specifically in
TN, basal-like tumors. PSMB9 and PSMB10 were among the top 20
PSMB8-correlated genes (r 0.89/0.83 and 0.68/0.54 in TCGA/META
TNBCs), reflecting coordinated co-expression of i-proteasome
subunits. These findings support the idea that i-proteasome
addiction could be a therapeutically targetable vulnerability in
breast cancer.
Figure 1. In vitro analysis of proteasome subunit expression and sensitivity to proteasome inhibitors.
(A) Proteasome subunit expression in breast cancer cell lines (Neve et al, 2006). (B) Inducible-to-constitutive subunit expression ratios (i:c) across
molecular breast cancer subtypes (stats: two-way ANOVA). (C) Linear regression and Pearson correlation analysis of the relationships between i:c and
sensitivity to bortezomib or carfilzomib (LD50, lethal dose 50%). Correlation coefficients (r) and regression fit values (r2) indicated. (D) Western analysis of
inducible subunits and the PA28 cap in lines with a range of bortezomib sensitivities. #MCF10A is a spontaneously immortalized breast-derived line
included for comparison. (E) Native in-gel proteasome activity assay with lysates from MDA-MB-468 and MCF7 with/without 2-h bortezomib treatment. (F)
Light microscope images of MDA-MB-468 and MCF7 48 h after bortezomib treatment (captured at 20× magnification, scale bar 50 μm). (G) Cell viability after
siRNA-mediated depletion of PSMB8 (i) or PSMB5 (ii). P-values in this figure were from unpaired, two-tailed t tests (pair-wise comparisons) or one-way
ANOVA tests (comparison across multiple groups): *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Source data are available for this figure.
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i-proteasome switching is driven by gene copy number
alterations (CNAs) and stratifies survival in TNBC
PSMB8 and PSMB9 genes are located within a 25-Mbp region on
chromosome 6p that is frequently affected by CNAs in cancer,
specifically, in the class-II locus of the HLA complex, which spans 4
Mbp on chromosome 6p.21 (Fig 4A). 6p gains are common in high-
grade malignancies (Santos et al, 2007), suggesting proteotoxic
stress resistance may be a fundamental requirement for cancers
with high metabolic activity. TCGA CNA data indicated that 6p is
affected by complex genomic instability in TNBC, marked by focal
gains and losses (Fig 4Ai). PSMB8/9 are gained in 46% and amplified
in 5.2% of TNBCs. The locus is also gained in ER+ and HER2+ cases,
but at lower frequency (17% and 27%; Fig 4Aii). Flanking PSMB8/9 are
co-altered genes encoding TAP1 and TAP2–ER membrane channels
that internalize proteasomal peptides and facilitate MHC class-I
antigen presentation (Fig 4Aii).
Quantifying proteasome subunit gene CNAs across BC sub-
types revealed that in addition to gains at 6p21.32 (PSMB8/9) in
TNBC, other events frequently affecting proteasome subunit
CN are losses at 17p13.2 and 16q22.1 (PSMB6, PSMB10; Fig 4B).
However, the genomic landscape of TNBC is unique in that
i-subunit gains occur concomitantly with loss of constitutive
subunit genes in more than half of cases (Fig 4B). This was also
evident within individual cases, with 65.3%, 31.2%, and 58.4% of
TNBCs exhibiting a predominance of inducible β1, β2, and β5
subunits, respectively (Fig 4C). Considering that subunit gene
copy number is a determinant of overall expression (Fig S3A),
these findings suggest that high i-proteasome expression in
TNBC is at least partly a consequence of selection pressure
during tumorigenesis.
Next, we used Kaplan–Meier analysis to investigate associations
between proteasome subunit expression and patient outcomes. In
independent TNBC datasets, i:c subunit expression ratios stratified
10-yr breast cancer–specific survival, but cases with the highest i:c
ratios had longer survival (Figs 4D and S2). Stratification was more
prominent among patients treated with chemotherapy and/or
radiotherapy (Figs 4D and S2). Therefore, althoguh i-proteasome
switching subverts metabolic stress in vitro and may confer a
selective advantage during TNBC development, in the clinical
setting, this seemed to be associated with favorable responses to
treatment.
Because (1) the i-proteasome is associated with both metabolic
homeostasis and antigen processing (2), multiple antigen-processing
Figure 2. In vitro activation of the unfolded protein response (UPR) by bortezomib in relation to proteasome subunit expression.
(A)Working model of UPR induction by three major signaling axes. BiP, binding immunoglobulin protein (GRP78). (B) qRT-PCR for ATF4 following bortezomib treatment.
(B, C) Log2 fold-change (FC) in XBP1s, apoptosis markers, and NFκB at multiple time points after bortezomib treatment (B, C: qRT-PCR). (D) Inverse association between
PSMB8/UPR induction and bortezomib sensitivity. (E) PSMB8 qRT-PCR (i) and bortezomib-induced cell death (ii) after pretreatment with IFN-γ. (F) IFN-γ–mediated
induction of IRF1 and antigen processing genes in MDA-MB-468/MCF7 cells transfected with scrambled (SCR) or IRF1-specific siRNAs. P-values in this figure were from
unpaired, two-tailed t tests: **P < 0.01; ***P < 0.001; ****P < 0.0001.
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machinery components are co-altered by genomic alterations in
TNBC, and (3) efficient antigen processing is conducive to anti-
tumor immunity in cancer generally; we reasoned that i-proteasome
overexpression could be both a vestige of metabolic addiction
and indicator of effective antigen presentation. The fact that the
link between i-proteasome and clinical outcome is specific to
patients treated with chemotherapy, and radiotherapy is con-
sistent with the evidence that these treatments promote immu-
nogenic tumor cell death by reactivating immune surveillance
(Dushyanthen et al, 2015). Indeed, i-subunit but not c-subunit
expression is inversely proportional to tumor purity (Fig S3B), and
the i:c expression ratio is highest in “basal-like, immune-activated”
TNBCs (Fig 4E) characterized by dense lymphocytic infiltrates
(Burstein et al, 2015).
This goes some way to reconciling the i-proteasome’s involve-
ment with both tumor development and responses to treatment,
but also raises the question of how much of the i-proteasome RNA
measured in tumor homogenate is attributable to tumor versus
stromal components. Unlike RNA expression, CNAs are intrinsic to
the tumor cell compartment, so we performed Kaplan–Meier
analysis of TNBCs after classifying them according to shifts in in-
ducible and constitutive proteasome subunit gene copy number. In
both METABRIC and TCGA datasets, TNBCs with higher overall
i-subunit copy number survived longer after the treatment (Fig 4F),
supporting the idea that higher levels of inducible proteasome
subunits are protective.
β5i is a favorable prognostic indicator associated with tumor-
specific immunity in TNBC
To validate these findings at the protein level, we performed
immunohistochemistry (IHC) analysis of β5i (PSMB8) in relation to
clinicopathologic variables and disease-specific survival using a
third cohort of 424 invasive breast tumors. We also analyzed the
MHC–I complex and proteasome activator subunit PA28β (PSME2),
which is similarly induced by IFN-γ but located outside the HLA
complex on chromosome 14q12 and less frequently affected by
CNAs (14.5% and 1.7% of TNBCs with PSME2 gain or amplification;
46% and 5.2% for PSMB8). β5i and PA28β were detected in the
nuclei and cytoplasm of normal mammary epithelial structures
and breast tumor cells, and MHC-I in cytoplasm and cell mem-
branes (Fig 5A and Tables S1–S3). On average, 83% of cases were
strongly positive for β5i, and 17% showed selective loss in the
tumor compartment (Figs 5A and S4A). Luminal-A–like tumors had
the most frequent expression overall, followed by basal-like
TNBCs (Fig S4B). Around one-third of all tumors exhibited loss
of MHC-I expression, but again expression was frequently
maintained in basal-like TNBCs (Fig S4C and D and Table S2). For
PA28β, 92% of cases were positive, with minimal differences
between breast cancer subtypes (Fig S4E and F and Table S3).
Among TNBCs, there was a direct relationship between levels of
β5i and PA28β, and they were both strongly associated with ex-
pression of MHC-I (Fig 5B), indicating that overall, there is coor-
dinated expression of MHC-I antigen processing and presentation
pathway components in TNBC.
We then reviewed matching hematoxylin and eosin–stained
whole sections to quantify immunologic correlates of β5i, PA28β,
and MHC-I expression: (1) the density of stromal TILs (Salgado et al,
2015), an established marker of treatment response in TNBC (Fig
5Ci), (2) the frequency of PD-L1 expression by TILs (Fig 5Cii), and (3)
tumor cells (Fig 5Ciii), a marker of effector T-cell responses in breast
cancer (Dushyanthen et al, 2015), and (4) the density of stromal cells
expressing high levels of MHC-II, a marker of professional APCs
(macrophages, dendritic cells, and B-cells; Fig 5Civ). Contingency
analysis showed that TNBCs with sustained expression of β5i and
MHC-I were more likely to be infiltrated by TILs and APCs and to
exhibit signs of antigen-specific T-cell engagement. These findings
are consistent with another report showing a direct relationship
Figure 3. i-proteasome genes are induced in claudin-low TNBCs and coordinately expressed with unfolded protein response genes.
(A, B) i:c Subunit expression ratios in breast cancer subtypes (METABRIC data, ANOVA test. *P < 0.05; ****P < 0.0001). (C) Gene set enrichment analysis plots showing
running enrichment scores (ESs) skewed toward the PSMB8-correlated transcriptome. NES, normalized ES.
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between tumor β5i, ER stress markers, MHC-I, and TILs (Lee et al,
2019).
To investigate the potential consequences of i-proteasome
components and/or MHC-I being dysregulated or lost in TNBC, we
performed the Kaplan–Meier analysis. Expression of β5i or MHC-I
modestly stratified survival (Fig 5Di, Ei, and Fi), but more striking
differences began to emerge when we considered the prognostic
significance of TILs in the tumor microenvironment of TNBCs that
maintained or lost antigen presentation components. TIL density
remains the most reliable prognostic indicator in TNBC (Loi et al,
2019; Luen et al, 2019), yet we found that this was specific to
tumors that retain expression of β5i, with little difference in
outcome over 20 yr among TNBCs that had lost β5i expression (Fig
5Dii). MHC-I and PA28β showed similar trends, although their
interactions with TILs density were not as significant (Fig 5Eii and
Fii). We reasoned that if β5i loss enabled immune escape, ex-
pression would be suppressed during metastatic progression.
Indeed, IHC analysis of β5i in brain metastases compared with
patient-matched primary breast tumor samples revealed lower
β5i expression in brain metastases in 16/34 of cases (Fig 5G;
paired t test P = 0.007).
Taken together, these findings suggest that antigen processing
via i-proteasome subunit β5i is associated with antitumor immune
responses. Given that we saw such a striking difference in TIL-based
prognostication depending on the β5i status, further cohort studies
are warranted to investigate predictive testing of i-proteasome
expression in conjunction with TILs assessment. We explored the
possibility that β5i-high TNBCs might be intrinsically more immuno-
genic by comparing themutation burdenof PSMB8 gained versus copy
number–neutral TNBCs in the TCGA cohort but found no evidence
Figure 4. Proteasome gene copy number aberrations related to clinical outcomes in breast cancer.
(A) TCGA 450k methylation array data for chromosome 6. (i) GISTIC calls for each probe shown as fractions of all triple-negative breast cancers (TNBCs). (ii) Zoomed
region encoding antigen-processing genes. Fractions of HER2+ and ER+ cases shown for comparison. (B) CN status of subunit genes in major disease subtypes. #,
instances of inducible subunit gain and constitutive subunit loss in a large percentage of TNBCs. (C) Violin plots showing i:c subunit CN switching (stats: pairwise
Kruskal–Wallis tests with Dunn’s correction for multiple comparisons; ****P < 0.0001). (D) Kaplan–Meier analysis of i:c subunit expression in TNBC patients treated with
(i) or without (ii) chemotherapy (CT) and/or radiotherapy (XRT). Q4/2-3/1, upper/mid/lower quartiles. Log-rank P-values shown. (E) i:c subunit expression ratios in TNBC
subtypes (Burstein et al, 2015): BLIA, basal-like immune-activated; BLIS, basal-like immune-suppressed; LAR, luminal androgen receptor-like; MES, mesenchymal.
Kruskal–Wallis test: ***P < 0.001, ****P < 0.0001. (F) Kaplan–Meier analysis of (i) METABRIC and (ii) TCGA TNBCs classified by whether i-subunit gene copy number
outnumbers that of constitutive subunit counterparts. Log-rank P-values shown.
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suggesting that their neoantigen load is higher than other TNBCs (Fig
S4G and H). Hence, β5i expression is unlikely to be causally associated
with a dense TIL phenotype, but probably potentiates tumor-specific
immune responses providing there is sufficient capacity.
We propose that the i-proteasome is exploited during TNBC
development to cope with proteotoxicity, but in immunologically
“hot” tumors (defined here as TILs occupying ≥20% of tumor-
associated stroma), this ultimately becomes a liability because
i-proteasome activity is linked to the efficacy of radiotherapy and
chemotherapy (Fig 6). Hence, adjuvant PI therapy could be
counterproductive in TNBC. On the other hand, increasing
i-proteasome activity could potentiate other first-line therapies.
Supporting this idea in principle, Tripathi and colleagues showed that
PSMB8/9 are suppressed in mesenchymal-like non–small cell lung
cancers, and that reactivating these genes with exogenous IFN-γ
restored a repertoire of MHC-I–bound tumor antigens that could
efficiently prime cytotoxic responses frompatient-derived peripheral
bloodmononuclear cells (Tripathi et al, 2016). 5-Aza-29-deoxycytidine
(decitabine), a cytosine analog and DNA methylation inhibitor, had
the same effect by suppressing methylation at PSMB8/9 enhancers
(Tripathi et al, 2016).
Considering these findings, our study supports the rationale
for trialing immunotherapy and DNA methyltransferase inhibitor
combinations in TNBC and other solid cancers (Jones et al, 2019).
Figure 5. Tumor compartment–specific expression of PSMB8 relates to clinicopathologic variables.
(A) Representative β5i, MHC-I, and PA28β IHC analysis of normal breast ducts and lobules (i) and invasive breast tumors (ii, iii), illustrating cases that exemplify
maintenance (ii) or selective loss (iii) of these class-I antigen presentation components. Cores are 1.0 mm i.d. and insets 140 μm2. (B) Contingency analysis of the
relationships between β5i, MHC-I, and PA28β in triple-negative breast cancer (TNBC). Fisher’s exact test P-values indicated *P < 0.05; **P < 0.01; ***P < 0.001. (C) Contingency
analysis of relationships between β5i, MHC-I, or PA28β, with TILs density (i), TILs PD-L1 positivity (ii), tumor cell PD-L1 positivity (iii), and the density of stromal APCs
(sAPCs; iv). Fisher’s exact test P-values indicated *P < 0.05; **P < 0.01; ***P < 0.001. (D, E, F) Kaplan–Meier analysis of TNBCs stratified by β5i, MHC-I, or PA28β (i) or by TIL
density after classifying TNBCs by their maintenance or loss of β5i, MHC-I, or PA28β (ii). HR, hazard ratio (95% confidence interval); log-rank P-values shown. (G) Change in
β5i IHC scores in brain metastases (BrM) compared with matching primary breast cancers (BC). Overall numbers of cases exhibiting increases (↑), decreases (↓), or no
change (–) are indicated. Paired, two-tailed t test P-value shown.
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Moreover, we recommend that additional cohort studies are
warranted to quantify the prognostic and predictive value of adding
β5i IHC to diagnostic assessment of TILs density in TNBC.
Materials and Methods
Cell lines and qRT-PCR
Cell lines were purchased from the American Type Culture Collection,
maintained in recommended culture conditions and regularly
screened for Mycoplasma (MycoAlert; Lonza). Cell line working stocks
used in this study were authenticated by STR profiling (Promega
GenePrint 10 System). For RNA inhibition studies, the cells were
transfected in six-well plates (3 × 105 cells/well) with 50 nM siRNAs
(GenePharma) using Lipofectamine RNAiMAX (Life Technologies). An
IncuCyte live-cell imaging system (Essen BioScience) was routinely
used to monitor cell attachment and growth in real time. Expression
analyses were performed 72 h post-transfection. For qRT-PCR, total
RNA was extracted from cultured cells using the RNeasy Mini Kit
(QIAGEN), cDNA was random-primed from 1 μg total RNA (MMLV RT;
Life Technologies), and qPCR was performed using SYBR Green
(Life Technologies; Table 1) and a CFX96 instrument (Bio-Rad).
Experiments were repeated three times.
Western analysis
Cells were trypsinized, centrifuged, washed, and then lysed in
Hepes (100 mM; pH 7.5), EDTA (2 mM), NaF (100 mM), sodium chloride
(500 mM), and trypsin inhibitor (50 μg/ml; Promega) with fresh
cOmplete Mini Protease Inhibitor (Roche). Protein lysates (5–20 μg)
were resolved by SDS–PAGE and probed overnight at 4°C with
antibodies against PSMB5 (#12919), PSMB6 (#13267), PSMB7 (#13207),
PSMB8 (#13726), and PA28g (#2142S) from Cell Signaling, used at
1:1,000, or β-tubulin (SAB4700544, 1:200; Merck). Chemiluminescent
detection was carried out using appropriate secondary antibodies
conjugated to horseradish peroxidase and the enhanced chem-
iluminescence kit (Amersham).
Native in-gel proteasome activity assay
Chymotrypsin-like activity was measured in freshly prepared cell
lysates as described previously (Elsasser et al, 2005) with minor
modifications. In brief, 5 × 106 cells were washed three times with
ice-cold PBS, pelleted by centrifugation (5 min, 250g at 4°C), and
then resuspended in lysis buffer (10 mM Tris–HCl [pH 7.8], 5 mM ATP,
and 5mMMgCl2) and kept on ice for 10min. The cells were sonicated
(MSE ultrasonic disintegrator, amplitude 15, 10 s at 4°C) followed by
centrifugation to remove cell debris (5 min, 16,000g, 4°C). Whole cell
lysates (40 μl) were separated on 3.5% non-denaturing polyacryl-
amide gels (Bio-Rad) in 10 mM Tris–HCl buffer supplemented with
ATP (0.5 mM; Sigma-Aldrich), MgCl2 (5 mM), glycerol (10% vol/vol),
and DTT (0.5 mM). Electrophoresis was performed at 35 V for 30 min
at 4°C, then the voltage was increased to 75 V for 4 h. Peptidolytic
activity was detected by incubating gels in Suc-LLVY-MCAc sub-
strate (dissolved in 50 mM Tris [pH 8.0], 5 mM MgCl2, 1 mM DTT, 2 mM
ATP, and 0.02% SDS for 10 min at 37°C). Proteasome bands were
identified by the release of highly fluorescent, free 7-amino-3-
methylcoumarin (AMC) under UV light (ChemiDoc; Bio-Rad).
Figure 6. Model contrasting the potential consequences of i-proteasome expression before and after treatment.
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In vitro bortezomib/carfilzomib sensitivity assays
A panel of basal-A (BT20 andMDA-MB-468), basal-B (Hs578T andMDA-
MB-231) luminal-like (BT-483, MCF7, and T47D), and luminal/HER2+
(SKBr3 and ZR751) cell lineswere used for cytotoxicity experiments. The
cells were routinely seeded in 96-well plates (2 × 104 cells/well) with
varying concentrations of PIs, harvested after 48 h, centrifuged at
1,300g, washed in PBS, and stained with 7-amino-actinomycin-D so-
lution (7AAD, 2 μg/ml; Invitrogen) for 10 min at room temperature. Cell
viability was determined with a FACSCalibur flow cytometer (Becton
Dickinson) and analyzed with FLOWJO software (Tree Star Inc.). Cell
survival data were normalized (0–100% defined as minimum and
maximum values), and regression analysis was performed using
GraphPad Prism software (v8.4) to define LD50 values.
Datasets and statistics
The following datasets were used in this study: (1) Affymetrix HG-
U133A gene expression array data: n = 51 breast cancer cell lines
(Neve et al, 2006), (2) RNASeq (V2 RSEM) mRNA expression z-scores: n
= 1,108, provisional TCGA breast tumor dataset (Cancer Genome Atlas
Network, 2012), (3) GISTIC 2.0 putative copy number calls: n = 1,080,
provisional TCGA breast tumor dataset (Cancer Genome Atlas
Network, 2012), (4) Illumina HT-12 gene expression array data: n =
1,980, METABRIC invasive breast cancer dataset (Curtis et al, 2012), (5)
mRNA expression array data: n = 256 TNBCs (IHC classification) and n
= 400 basal-like tumors (PAM50 classifier) from KM plotter for breast
cancer (Gyorffy et al, 2010), and (6) computationally derived pan-
cancer tumor purity assessment of TCGA samples (Aran et al, 2015).
Gene set enrichment analysis was performed using the GSEAPrer-
anked module of GenePattern (weighted scoring scheme, 1,000
permutations) (Reich et al, 2006). Gene sets were extracted from
the Gene Ontology Consortium database (The Gene Ontology
Consortium, 2019) using the search term “UPR.” Preparation of
graphs and all other statistical tests were performed using GraphPad
Prism software (v8.4). Statistical tests are described in figure legends.
Clinical sample cohorts and IHC analyses
IHC analysis of archival specimens and clinicopathologic data were
approved by human research ethics committees at The Royal
Brisbane and Women’s Hospital (2005-022) and The University of
Queensland (2005000785). IHC analyses were performed on two
separate cohorts:
1. The Queensland follow-up cohort. This resource was built from
archival tissue specimens of breast cancer patients treated in
Queensland between 1987 and 1992, sourced from the statewide
Pathology Service, Pathology Queensland, and sampled in duplicate
on tissue microarrays (TMAs). Median follow-up is 13.9 yr (range
























Relevance of proteasome inhibitor therapy in TNBC Adwal et al. https://doi.org/10.26508/lsa.201900562 vol 3 | no 7 | e201900562 9 of 12
0.3–41 yr), median age at diagnosis 59.3 yr, and there were 199 breast
cancer–specific deaths at the 25-yr censor point (~37.7%).
2. A second cohort of brain metastases and patient-matched
primary breast tumor specimens collected between 2001 and
2013, also sampled in TMAs.
Clinical and pathology data were extracted from diagnostic
reports, our internal diagnostic histopathology review (SRL) and the
Queensland Cancer Registry. Analysis included cross-referencing to
clinicopathologic parameters that were assessed and published
previously (e.g., expression of ER, PR, and HER2; histological grade
and subtype [Junankar et al, 2015; Zhang et al, 2015; Burgess et al,
2016; Hernandez-Perez et al, 2017; McCart Reed et al, 2018;
Raghavendra et al, 2018; Wiegmans et al, 2019]). For IHC, 4-μm
TMA sections were heat-retrieved in using a Decloaking Chamber
and blocked for 15 min at room temperature before staining (Table
2). The MACH 1 Universal HRP-Polymer Detection Kit was used for
detection. Reagents and equipment were from Biocare Medical unless
otherwise specified. For image analysis, hematoxylin-counterstained
sections were scanned at 40× magnification on an Aperio AT Turbo
slide scanner (Leica Biosystems). De-identified digital TMA core im-
ages were scored by one assessor and reviewed by a second. The
maximum scores of duplicate TMA cores were calculated for each
case, except for β5i, MHC-I, and PA28β, where minimum scores were
used because the disease-associated phenotypes were a loss of
expression. Associations between biomarkers and clinicopathologic
variables were investigated using chi-squared, Fisher’s exact, and log-
rank tests (GraphPad Prism v8.4).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900562.
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